419 related articles for article (PubMed ID: 27696084)
1. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.
Mantha S; Laube E; Miao Y; Sarasohn DM; Parameswaran R; Stefanik S; Brar G; Samedy P; Wills J; Harnicar S; Soff GA
J Thromb Thrombolysis; 2017 Feb; 43(2):166-171. PubMed ID: 27696084
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
3. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
6. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
7. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
Davies GA; Lazo-Langner A; Gandara E; Rodger M; Tagalakis V; Louzada M; Corpuz R; Kovacs MJ
Thromb Res; 2018 Feb; 162():88-92. PubMed ID: 28416213
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Kobayashi T; Niwa A; Matsuo H; Yokoi H; Koga M; Yamazaki T; Hirayama A;
Circ J; 2020 Oct; 84(11):1912-1921. PubMed ID: 32981924
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
12. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
15. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
20. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
